Company Encyclopedia
View More
name
Tenax Therap
TENX.US
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc.
1.946 T
TENX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tenax Therapeutics Executives to Present at Major Healthcare Investor Conferences

    Tenax Therapeutics Inc. will present at the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025. The events will include a fireside chat with President & CEO Chris Giordano and Chief Medical Officer Stuart Rich, M.D. Live and archived webcasts will be available on the company's investor relations webpage.

    Reuters·
    US
    TENX
    +1.74%
    Reuters·
    US
    TENX
    +1.74%

    CEO Giordano Buys 2,605 ($20K) Of Tenax Therapeutics Inc [TENX]

    Giordano Christopher Thomas Chief Executive Officer of Tenax Therapeutics Inc [TENX] filed a Form 4 on November 20, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/18/25-11/20/25TransactionPurchaseShares2,605Price$7.68Value$20,000Ending Holdings: 2,605 - DirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    TENX
    +1.74%
    Reuters·
    US
    TENX
    +1.74%

    Tenax Therapeutics CEO Christopher Thomas Giordano Reports Acquisition of Common Shares

    Christopher Thomas Giordano, CEO of Tenax Therapeutics Inc., has acquired common shares of the company. This event was reported through the U.S. SEC's EDGAR system. The information is provided by Public Technologies and is for informational purposes only.

    Reuters·
    US
    TENX
    +1.74%
    Reuters·
    US
    TENX
    +1.74%

    Dir Almenoff Buys 1,993 ($14.9K) Of Tenax Therapeutics Inc [TENX]-Amended

    Almenoff June Sherie Director of Tenax Therapeutics Inc [TENX] filed a Form 4/A on November 20, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/17/25-11/18/25TransactionPurchaseShares1,993Price$7.50Value$14,945Ending Holdings: 1,993 - IndirectFor a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    TENX
    +1.74%
    Reuters·
    US
    TENX
    +1.74%

    Director’s Bold Move: A Significant Investment in Tenax Therapeutics!

    Director June Sherie Almenoff invested in Tenax Therapeutics by purchasing 1,993 shares for $14,933, signaling confidence in the company. Despite a Q3 net loss of $15.8 million due to increased R&D expenses, Tenax maintains a strong cash position of $99.4 million. The company is advancing Phase 3 trials and expects a new patent grant in Europe. However, Spark's AI Analyst rates TENX as "Underperform" due to financial challenges and reliance on equity financing.

    Tip Ranks·
    US
    TENX
    +1.74%
    Tip Ranks·
    US
    TENX
    +1.74%
    © 2025 Longbridge｜Disclaimer